Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONTSE:GUDNYSEARCA:THCXNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.04+2.0%$1.95$1.60▼$2.54$786.79M1.031.35 million shs1.94 million shsGUDKnight TherapeuticsC$6.05+0.5%C$5.89C$5.09▼C$6.45C$611.96M0.567,197 shs9,509 shsTHCXAXS Cannabis ETF$16.60$16.60$14.90▼$25.40$141.07M1.7115,071 shsN/ATLRYTilray Brands$0.53+9.4%$0.43$0.35▼$2.15$542.20M1.8229.90 million shs43.04 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+2.00%+6.81%+5.70%+19.30%-12.07%GUDKnight Therapeutics+0.33%+4.70%+3.79%+2.73%+4.70%THCXAXS Cannabis ETF0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands+9.44%+28.76%+32.75%-10.33%-69.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group2.306 of 5 stars0.05.00.00.01.90.02.5GUDKnight TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATHCXAXS Cannabis ETFN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands1.8229 of 5 stars3.11.00.00.02.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AGUDKnight Therapeutics 3.50Strong BuyC$7.1518.18% UpsideTHCXAXS Cannabis ETF 2.54Moderate Buy$16.60N/ATLRYTilray Brands 2.25Hold$1.92260.95% UpsideCurrent Analyst Ratings BreakdownLatest GUD, THCX, CRON, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ BuyC$6.504/14/2025TLRYTilray BrandsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilray BrandsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M6.69$0.00 per share4,384.08$2.90 per share0.70GUDKnight TherapeuticsC$348.70M1.75C$1.57 per share3.85C$7.65 per share0.79THCXAXS Cannabis ETFN/AN/AN/AN/AN/AN/ATLRYTilray Brands$788.94M0.68N/AN/A$4.14 per share0.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.1315.6968.00N/A39.69%-0.07%-0.07%8/6/2025 (Estimated)GUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/ATHCXAXS Cannabis ETFN/AN/A0.00∞N/AN/AN/AN/AN/ATLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest GUD, THCX, CRON, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/8/2025Q3 2025TLRYTilray Brands-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ATHCXAXS Cannabis ETF$0.724.34%N/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A27.8026.75GUDKnight Therapeutics7.523.361.79THCXAXS Cannabis ETFN/AN/AN/ATLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%GUDKnight Therapeutics12.58%THCXAXS Cannabis ETFN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%GUDKnight Therapeutics45.62%THCXAXS Cannabis ETFN/ATLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.68 million357.53 millionOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableTHCXAXS Cannabis ETFN/A8.50 millionN/ANot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableGUD, THCX, CRON, and TLRY HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Stock Price Up 9.4% - Still a Buy?July 4 at 12:13 PM | marketbeat.comHere’s why the Tilray Brands stock price has implodedJuly 3 at 5:07 PM | invezz.comIStock Traders Buy Large Volume of Tilray Brands Call Options (NASDAQ:TLRY)July 3 at 2:09 PM | marketbeat.comCannabis Stocks To Keep An Eye On - July 3rdJuly 3 at 1:46 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading 4.1% Higher - Here's WhyJuly 2 at 1:37 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 1.3% - Should You Sell?July 1 at 3:40 PM | marketbeat.comBeers, Live Music, Hot Dogs and Fireworks: Everything You Need for an Epic 4th Of July CelebrationJuly 1 at 8:19 AM | financialpost.comFBreckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles TolandJuly 1 at 7:04 AM | financialpost.comFBreckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles TolandJuly 1 at 7:00 AM | globenewswire.comTLRY - Tilray Brands Inc News - MorningstarJune 28, 2025 | morningstar.comMTilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for InvestorsJune 27, 2025 | zacks.comTilray Brands (NASDAQ:TLRY) Shares Up 3.9% - Should You Buy?June 26, 2025 | marketbeat.comTilray Brands (NasdaqGS:TLRY) Advances Medical Cannabis Research With New Bioavailability StudyJune 26, 2025 | finance.yahoo.comTilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD FormulationsJune 26, 2025 | finance.yahoo.comMontauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider FoundationJune 26, 2025 | globenewswire.comTLRY Stock - Tilray Brands Inc Stock Price Quote - XTSE - MorningstarJune 26, 2025 | morningstar.comMHere Is A List Of 3 Canadian Marijuana Stocks To Watch 2025June 25, 2025 | marijuanastocks.comMTilray Medical Launches “Good Supply” Cannabis Brand in GermanyJune 25, 2025 | insidermonkey.comTilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic UseJune 24, 2025 | finance.yahoo.comTilray sets medical cannabis milestone in ItalyJune 24, 2025 | msn.comTilray Brands Stock Price, Quotes and Forecasts | NASDAQ:TLRY - BenzingaJune 24, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeMicron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingBy Thomas Hughes | June 26, 2025View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment Micron’s Big Q3 Drives Applied Materials’ Bullish OutlookBy Leo Miller | July 3, 2025View Micron’s Big Q3 Drives Applied Materials’ Bullish OutlookGUD, THCX, CRON, and TLRY Company DescriptionsCronos Group NASDAQ:CRON$2.04 +0.04 (+2.00%) Closing price 07/3/2025 03:16 PM EasternExtended Trading$2.04 0.00 (-0.25%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$6.05 +0.03 (+0.50%) As of 04:00 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.AXS Cannabis ETF NYSEARCA:THCX$16.60 0.00 (0.00%) As of 03/1/2024The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.Tilray Brands NASDAQ:TLRY$0.53 +0.05 (+9.44%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.54 +0.00 (+0.75%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
